Inclusion Criteria:

- Advanced metastatic colorectal (stage IV) cancer verified by biopsy within 12 months
prior to signing consent

- Chemotherapy-naive patients or patients who received chemotherapy in an adjuvant
setting that ended at least 6 months prior to signing consent. No previous treatment
with oxaliplatin

- CT-scan or MRI of thorax, abdomen and pelvis; within ≤4 weeks before start of
chemotherapy

- Evaluable disease and one measurable site of disease according to RECIST 1.1 criteria
(at least 10 mm for CT-scan or MRI)

- Neurological examination with no pathological findings

- ≥18 years

- WHO performance status 0≤2 and Life expectancy ≥ 3 months

- Adequate haematological function , Hb ≥ 100 g/L, ANC ≥ 1.5 x 10^9/L, platelets ≥ 100
x 10^9/L

- Serum calcium, magnesium, zinc and potassium within normal limits

- Adequate renal and hepatic functions: creatinine clearance >50 cc/min, total
bilirubin ≤ 1.25 times upper normal limits, ASAT and ALAT ≤ 3 times upper normal
limits

- INR ≤1.5x ULN, unless receiving therapeutic anticoagulation

- Negative pregnancy test for females of child-producing potential

- Written informed consent given

Exclusion Criteria:

- Tumours other than colorectal adenocarcinomas except for curatively treated non
melanoma skin cancer or in situ carcinoma of the cervix

- Evidence of central nervous system metastases

- Unresolved bowel obstruction or sub-obstruction, uncontrolled Crohn's disease or
ulcerative colitis

- History of cardiac disease with a New York Heart Association (NYHA) Class II or
greater congestive heart failure, myocardial infarction or unstable angina in the
past six (6) months prior to Day 1 of treatment and serious arrhythmias requiring
medication for treatment

- Prolonged QTC interval >450 msec

- Known history of stroke or cerebrovascular accident in the past six (6) months

- Current chronic diarrhoea

- Any known chronic infection or chronic illness causing immunodeficiency

- Any uncontrolled serious illness or medical condition

- Existing peripheral neuropathy

- Received mangafodipir at any time

- Welders, mine workers or other workers in occupations (current or past) where high
manganese exposure is likely

- Pre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's etc.)
or neuromuscular disorder (Multiple sclerosis, Amyotrophic lateral sclerosis, Polio,
hereditary neuromuscular disease)

- Major psychiatric disorder (major depression, psychosis)

- Cirrhosis or history of obstructive jaundice